Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial

Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)

(2015) Florian M Wagenlehner et al.   LANCET

Impact of extended-spectrum β-lactamase-producing organisms on clinical and economic outcomes in patients with urinary tract infection

(2014) Shawn H. MacVane et al.   Journal of Hospital Medicine

Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012)

(2014) Helio S. Sader et al.   JOURNAL OF INFECTION

Healthcare-associated urinary tract infections in hospitalized urological patients—a global perspective: results from the GPIU studies 2003–2010

(2014) Mete Cek et al.   WORLD JOURNAL OF UROLOGY

Temporal trends and risk factors for extended-spectrum beta-lactamase-producing Escherichia coli in adults with catheter-associated urinary tract infections

(2014) Joseph T Spadafino et al.   Antimicrobial Resistance and Infection Control

Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2011-2012)

(2013) David J. Farrell et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Appropriate Antibiotic Use for Patients With Urinary Tract Infections Reduces Length of Hospital Stay

(2013) V. Spoorenberg et al.   CLINICAL INFECTIOUS DISEASES

Antimicrobial Susceptibility of Inpatient Urinary Tract Isolates of Gram-Negative Bacilli in the United States: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) Program: 2009−2011

(2013) Sam K. Bouchillon et al.   CLINICAL THERAPEUTICS

Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative Bacilli

(2013) George G. Zhanel et al.   DRUGS

Levofloxacin for the treatment of pyelonephritis

(2013) Cédric Rafat et al.   EXPERT OPINION ON PHARMACOTHERAPY

Emerging resistance problems and future perspectives in pharmacotherapy for complicated urinary tract infections

(2013) Yen-Hsu Chen et al.   EXPERT OPINION ON PHARMACOTHERAPY

Health Care–Associated Infections

(2013) Eyal Zimlichman et al.   JAMA Internal Medicine

Declining susceptibilities of gram-negative bacteria to the fluoroquinolones: Effects on pharmacokinetics, pharmacodynamics, and clinical outcomes

(2012) Matthew J. Labreche et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Costs of Healthcare- and Community-Associated Infections With Antimicrobial-Resistant Versus Antimicrobial-Susceptible Organisms

(2012) Matthew J. Neidell et al.   CLINICAL INFECTIOUS DISEASES

Antimicrobial susceptibility of Enterobacteriaceae, including molecular characterization of extended-spectrum beta-lactamase–producing species, in urinary tract isolates from hospitalized patients in North America and Europe: results from the SMART study 2009–2010

(2012) Daryl J. Hoban et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Antimicrobial-Resistant Pathogens Associated with Healthcare-Associated Infections Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010

(2012) Dawn M. Sievert et al.   INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

Epidemiology, risk factors and comorbidity for urinary tract infections caused by extended-spectrum beta-lactamase (ESBL)-producing enterobacteria

(2012) L. S. Briongos-Figuero et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Diagnosis, Prevention, and Treatment of Catheter-Associated Urinary Tract Infection in Adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America

(2011) Thomas M. Hooton et al.   CLINICAL INFECTIOUS DISEASES

Epidemiology, treatment and prevention of healthcare-associated urinary tract infections

(2011) F. M. E. Wagenlehner et al.   WORLD JOURNAL OF UROLOGY

Escherichia coliSequence Type ST131 as the Major Cause of Serious Multidrug‐ResistantE. coliInfections in the United States

(2010) James R. Johnson et al.   CLINICAL INFECTIOUS DISEASES

Impact of discordant empirical therapy on outcome of community-acquired bacteremic acute pyelonephritis

(2010) Seung Soon Lee et al.   JOURNAL OF INFECTION